Skip to content

CHronic Nonbacterial Osteomyelitis International Registry

CHronic Nonbacterial Osteomyelitis International Registry (CHOIR)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04725422
Acronym
CHOIR
Enrollment
2000
Registered
2021-01-26
Start date
2018-08-01
Completion date
2050-08-31
Last updated
2024-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Nonbacterial Osteomyelitis, Chronic Recurrent Multifocal Osteomyelitis

Brief summary

The objective of the study is to establish a prospective disease registry for chronic recurrent multifocal osteomyelitis (CRMO)/chronic nonbacterial osteomyelitis (CNO) in order to investigate the natural history of the disease and the responses of patients to different clinical managements over 10 years.

Detailed description

Chronic nonbacterial osteomyelitis (CNO) is an autoinflammatory bone disease that mainly affects children and adolescents. Clinical presentations range from mild and sometimes limited unifocal disease to severe, chronically active or recurrent inflammation of multiple bones. The latter is referred to as chronic recurrent multifocal osteomyelitis (CRMO). Here we will use the term CNO to refer to the entire spectrum of this disease. CNO can be complicated by vertebral compression fractures, kyphosis, and leg length discrepancy when it is not recognized early or treated adequately. The diagnosis of CNO is made by excluding alternatives in the differential diagnosis including malignancy (leukemia, lymphoma, and primary or metastatic bone tumors), Langerhans cell histiocytosis, and infection. Clinical assessment in conjunction with serum inflammatory parameters and imaging studies, particularly magnetic resonance imaging (MRI), are crucial for the diagnosis and monitoring of disease activity of CNO1. Because of significant variation in clinical treatment practices among pediatric rheumatologists, standardized treatment regimens (consensus treatment plans, CTPs) have been developed within the Childhood Arthritis and Rheumatology Research Alliance (CARRA), a North American organization comprised of pediatric rheumatologists and researchers, for CNO patients with an NSAID-refractory course and/or with active spinal lesions2. These CTPs provide an opportunity for pediatric rheumatologists to conduct comparative effectiveness research on CNO through prospective data collection. CRMO/CNO workgroup is comprised of pediatric rheumatologists from North America as well as international colleagues who are interested in collaborating in CNO research. Furthermore, risk factors of severe disease have been described by Wipff et al. based on a large retrospective cohort study3. Their results may be validated by an independent prospective cohort study. To date, there has been only one prospective study on CNO since its first description in 19724. Therefore, we propose to establish this international registry of patients with CNO to accomplish above goals. Long-term outcomes of CNO remains unknown due to the lack of prospective study. It has been estimated that at least 50% of CNO patients continue to need medications for CNO during adulthood. Our study will collect the clinical data and provide valuable data to characterize the long-term outcomes.

Interventions

DRUGMethotrexate

second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs

DRUGSulfasalazine

second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs

DRUGLeflunomide

second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs

DRUGPamidronate

second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs

DRUGZoledronic acid

second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs

DRUGEtanercept

second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs

DRUGAdalimumab

second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs

second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs

DRUGInfliximab

second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs

DRUGGolimumab

second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs

DRUGNSAID

first-line treatment

Sponsors

Boston Children's Hospital, Boston, MA, USA
CollaboratorOTHER
Hospital for Special Surgery, New York
CollaboratorOTHER
Joseph M Sanzari Children's Hospital, Hackensack University Medical Center, Hackensack, NJ, USA
CollaboratorUNKNOWN
Riley Children's Hospital, Indianapolis, IN, USA
CollaboratorUNKNOWN
University of North Carolina, Chapel Hill, NC, USA
CollaboratorUNKNOWN
Royal Children's Hospital
CollaboratorOTHER
Hacettepe University
CollaboratorOTHER
Bambino Gesù Children's Hospital, Rome, Italy
CollaboratorUNKNOWN
University of British Columbia, Vancouver, BC, Canada
CollaboratorUNKNOWN
Meyer Children's Hospital, Florence, Italy
CollaboratorUNKNOWN
Mansoura University
CollaboratorOTHER
University of Utah, Salt Lake City, UT, USA
CollaboratorUNKNOWN
University of Iowa Carver College of Medicine, Iowa City, IA, USA
CollaboratorUNKNOWN
Ann & Robert Lurie Children's Hospital of Chicago, Chicago, IL, USA
CollaboratorUNKNOWN
Palacky University Olomouc Institute of Molecular and Translational Medicine, Olomouc, Czechia
CollaboratorUNKNOWN
Alder Hey Children's NHS Foundation Trust Hospital, Liverpool, UK
CollaboratorUNKNOWN
University of Calgary, Calgary, Alberta, Canada
CollaboratorUNKNOWN
Seattle Children's Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
No minimum to 21 Years
Healthy volunteers
No

Inclusion criteria

* \- Age at enrollment is equal to or younger than 21 years of age * Presence of bone edema on STIR or T2 fat saturation sequence on MRI within 12 weeks of enrollment * Whole body imaging evaluation (either WB MRI or bone scintigraphy) * Bone biopsy to exclude infection or malignancy unless bone lesions follow typical distribution or there is IBD, psoriasis, or palmar plantar pustulosis

Exclusion criteria

* \- History of or current malignancy * Current infectious osteomyelitis * Contraindication to the selected treatment agent

Design outcomes

Primary

MeasureTime frameDescription
The change of CNO disease activity score3-6 monthsDisease activity score is calculated as the sum of number of clinical lesion count, patient global assessment (0-10), physician global assessment (0-10)

Secondary

MeasureTime frameDescription
Total number of CNO lesions on MRI3-6 monthsThe total number of CNO lesions from MRI as previously described (Zhao, et al. J Rheum 2019) will be used to monitor response in a subset
Safety monitoring5 yearsSerious adverse events including infections that require IV antibiotics, malignancy, hematological, hepatic, dermatological side effects will be reported

Countries

United States

Contacts

Primary ContactYongdong (Dan) Zhao, MD, PhD
crmoresearch@seattlechildrens.org206-987-2000

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026